Angelo DePalma
Angelo DePalma
Latest posts from :
Angelo DePalma explores prescription to over-the-counter (Rx to OTC) switches...
Angelo DePalma explores what it costs to bring a new drug to market—and why...
Angelo DePalma explores how many pharma firms are focusing on improved...
Angelo DePalma examines the commercial future of the biosimilars market
Angelo DePalma explores how drug firms can re-invent the pharma supply chain to...
Angelo DePalma outlines the prospects for the global market for pain management...
Pharma firms are betting that branded generics will become a powerful source of...
Angelo DePalma investigates how emerging collaborative partnerships could alter...
*Anonymous patient-level data (APLD) is an attractive information source for ...
*Pharma is unprepared for the blockbuster patent expirations due over the ...